Valuation: Viking Therapeutics, Inc.

Market Cap 4.78B 4.18B 3.85B 3.57B 6.77B 456B 6.88B 46.15B 18.09B 224B 17.93B 17.54B 776B P/E 2026 *
-8.56x
P/E 2027 * -8.89x
Enterprise Value 4.33B 3.78B 3.49B 3.23B 6.13B 413B 6.23B 41.8B 16.38B 203B 16.24B 15.89B 702B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.21%
Yield 2026 *
-
Yield 2027 * -
1 day+2.95%
1 week+9.88%
Current month+5.46%
1 month+40.75%
3 months+17.71%
6 months+28.60%
Current year+16.94%
1 week 37.1
Extreme 37.1
42.79
1 month 27.16
Extreme 27.16
42.79
Current year 25.77
Extreme 25.77
42.79
1 year 22.96
Extreme 22.959
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 2012-09-23
Director of Finance/CFO 55 2021-01-03
Chief Tech/Sci/R&D Officer 57 2026-06-10
Director TitleAgeSince
Chairman 68 2015-04-30
Chairman 60 2012-09-23
Director/Board Member 53 2014-04-30
Date Insider Type Main position Quantity % Market Cap.
05-31Free

Chief Technology Officer

190,000 0.1636%
03-09Buy

Executive/Senior Manager

4,475 0.0039%
01-11Free

Executive/Senior Manager

180,000 0.1592%
Change 5-day change 1-year change 3-year change Capi.($)
+2.95%+9.88%+35.33%+167.49% 4.78B
-0.23%-4.31%+63.78%+126.11% 56.98B
+4.91%-0.19%+73.70%+92.14% 53.58B
+1.48%+5.97%+22.59%+495.47% 25.63B
-0.59%-4.68%-16.82%-12.99% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-1.02%+2.54%+37.40%-25.01% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+3.51%+53.81% - 14.13B
+1.76%+2.24%+29.57%+195.70% 14.35B
Average +1.36%+1.76%+55.01%+154.10% 24.7B
Weighted average by Cap. +1.43%-0.11%+56.95%+143.44%

Financials

2026 *2027 *
Net sales - -
Net income -563M -493M -454M -420M -798M -53.74B -811M -5.44B -2.13B -26.39B -2.11B -2.07B -91.41B -587M -514M -474M -438M -832M -56.07B -846M -5.67B -2.22B -27.53B -2.21B -2.16B -95.37B
Net Debt -450M -394M -363M -336M -638M -42.99B -649M -4.35B -1.71B -21.11B -1.69B -1.65B -73.13B -523M -458M -422M -391M -742M -49.96B -754M -5.06B -1.98B -24.54B -1.97B -1.92B -84.99B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
59
Date Price Change Volume
26-07-09 US$41.14 +2.95% 1,722,342
26-07-08 US$39.96 -5.15% 3,341,213
26-07-07 US$42.13 +8.83% 4,359,821
26-07-06 US$38.71 +3.39% 2,122,614
26-07-02 US$37.44 -0.11% 2,487,336
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
41.14USD
Average target price
92.58USD
Spread / Average Target
+125.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock